

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Metis TechBio Co., Ltd.

剂泰科技(北京)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 7666)

VOLUNTARY ANNOUNCEMENT

METIS TECHBIO ANNOUNCES A PRECLINICAL TCE LICENSING COLLABORATION WITH DEERFIELD OF UP TO US\$1.6 BILLION

This announcement is made by Metis TechBio Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**” or “**Metis TechBio**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company has entered into a global exclusive license agreement with Boulevard Bio, Inc. (“**Boulevard Bio**”), a US-based biotechnology company under Deerfield Management Company, L.P. (“**Deerfield**”), granting it the global rights to develop, manufacture and commercialise MTS-128, a proprietary trispecific TCE (T Cell Engager) (the “**Collaboration**”). Under the Collaboration agreement, Metis TechBio will receive an upfront payment of US\$20 million, and is eligible to receive up to US\$1.6 billion in development, regulatory and commercial milestone payments, plus tiered sales royalties based on product sales.

MTS-128 is a next-generation trispecific TCE independently developed by Metis TechBio, powered by its NanoForge platform. Unlike conventional antibody discovery approaches, MTS-128 was designed and optimised using the NanoForge platform, representing a key project in Metis TechBio’s AI-enabled innovative therapy development. Compared with traditional bispecific TCEs, trispecific TCEs can simultaneously modulate more biological mechanisms, offering unique potential advantages in enhancing target cell killing efficiency, increasing therapeutic window, improving selectivity and safety profiles. The successful development of MTS-128 demonstrates Metis TechBio’s capability to deeply integrate artificial intelligence with protein drug design, and validates the potential of NanoForge to continuously generate innovative assets.

ABOUT METIS TECHBIO

Metis TechBio was co-founded in 2020 by Dr. Hongming Chen, a member of the U.S. National Academy of Engineering, along with MIT scientists Dr. Tsai-Ta Lai and Dr. Wenshou Wang. The Company was successfully listed on The Stock Exchange of Hong Kong Limited on May 13, 2026 as the “world’s first listed company of AI drug delivery”. The Company has independently developed NanoForge, the world’s first AI-driven nano-delivery platform, and owns the world’s largest proprietary LNP lipid library with over 10 million lipids. Based on NanoForge, the Company has built four core solutions: AiLNP (AI nano-delivery system design platform), AiRNA (AI mRNA sequence design platform), AiProtein (AI protein design platform), and AiTEM (AI small molecule formulation design platform).

ABOUT DEERFIELD

Deerfield is an investment management firm focused on the healthcare sector, dedicated to advancing healthcare through investment, intelligence and philanthropy. The company collaborates broadly with the global healthcare ecosystem, connecting talent, capital, innovative ideas and technology in an open and collaborative manner to jointly drive healthcare innovation. For more information, please visit www.deerfield.com.

ABOUT BOULEVARD BIO

Boulevard Bio is a biotechnology company focused on the development of innovative immunotherapies. Founded with the support of Deerfield, it is committed to advancing the development of innovative therapies with breakthrough potential to provide new treatment options for patients worldwide.

FORWARD-LOOKING STATEMENTS

There is no assurance that any forward-looking statements contained in this announcement regarding the Group’s business development, or any matter, will be achieved, will actually occur, will be realised or are complete or accurate. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Metis TechBio Co., Ltd.
Tsai-Ta Lai

Chairman of the Board, executive Director and chief executive officer

Hong Kong, June 30, 2026

As of the date of this announcement, the Board comprises Dr. Tsai-Ta Lai, Dr. Hongming Chen and Dr. Wenshou Wang as executive Directors; Mr. Hantao Huang and Ms. Yuan Gong as non-executive Directors; and Mr. Frank Yee Chon Lyn, Dr. Jin Li and Dr. Peter Edward Lobie as independent non-executive Directors.